Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) with N-terminal trans-3-hexenoyl modification, designed for laboratory research on endocrine signaling and metabolic regulation. It...
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) with N-terminal trans-3-hexenoyl modification, designed for laboratory research on endocrine signaling and metabolic regulation. It has been studied in controlled settings for its interactions with pituitary receptors and effects on hormone release pathways in preclinical models.
Every compound is manufactured to research-grade standards and intended strictly for laboratory and research use. Consistent quality you can build a reproducible protocol around.
Batch number on every vial
Published Certificates of Analysis
Purity verified by third-party testing
Temperature-sensitive compounds are stored and shipped under controlled conditions, so material arrives in the state your research requires. Expert support on hand at every step.
Tesamorelin (8mg), also known as TH9507, is a stabilized analog of endogenous GHRH engineered to enhance resistance to enzymatic degradation. Its structure incorporates modified amino acids and a trans-3-hexenoyl group, contributing to improved stability in experimental models.
The peptide has a chemical formula of C₂₂₁H₃₆₆N₇₂O₆₇S and a molecular weight of 5136 g/mol, reflecting its high molecular complexity. Tesamorelin has been studied for its involvement in endocrine signaling, metabolic regulation, and growth hormone–related pathways in preclinical and controlled laboratory environments.
For laboratory research use only.
Tesamorelin (8mg) is being researched for its role in hormonal signaling and metabolic regulation, particularly in studies examining growth hormone pathways. In laboratory settings, it has been studied for how peptide-based signals influence endocrine activity, lipid metabolism, and energy balance.
Research applications often focus on systems involved in pituitary signaling, hormone release dynamics, and metabolic adaptation. Tesamorelin is also being investigated in experimental models exploring how modified peptides affect cellular communication and systemic metabolic processes.
These studies are typically conducted in in vitro systems and animal models, where precise control over experimental variables allows for detailed observation of peptide activity.
Preclinical investigations of Tesamorelin and similar peptides report dosing parameters commonly expressed in microgram-per-kilogram (µg/kg) ranges in animal models. In vitro studies frequently use defined concentration ranges to evaluate cellular responses to peptide exposure.
Observed findings suggest that GHRH analogs may modulate biological pathways involved in hormone signaling, metabolic coordination, and cellular activity. These effects depend on the experimental design and remain under investigation.
Laboratory data also indicate that structurally modified peptides, such as Tesamorelin, may exhibit enhanced stability and prolonged interactions with target systems, supporting their use in mechanistic research.
Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
Subscribe for exclusive offers and updates on new arrivals